Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
479 Leser
Artikel bewerten:
(2)

Exyte to build Dexcom's first manufacturing facility in Asia

STUTTGART, Germany and PENANG, Malaysia, April 15, 2021 /PRNewswire/ -- Exyte, world-renowned for the design and construction of high-tech facilities, has been awarded a fast-track project for Dexcom in Penang, Malaysia. This is the first manufacturing facility for the U.S.-based diabetes care technology provider outside the United States.

Dexcom headquarters in San Diego, USA.

Exyte is proud to support Dexcom's strategic growth plans as it expands manufacturing into Asia for the first time. Located in Batu Kawan, Penang, and with 1.8 million square feet of gross floor area, the project will house a manufacturing facility for continuous glucose monitoring (CGM) systems. Key parts of the facility include multi-story cleanrooms, a warehouse with dock leveller, a three-story Central Utility Building (CUB), a seven-story office building with a canteen and recreational area as well as a seven-level multi-story parking structure.

Exyte's value-added engineering capabilities and experienced team of engineers provide the right fit to complete the state-of-the-art facility in an efficient manner. The project will enable Dexcom to quickly expand CGM production, increasing the number of systems it can deliver worldwide to meet growing demands.

"We selected Exyte as the design and construction partner for our first manufacturing facility in Asia due to their excellent record of delivering fast-track projects of this magnitude and complexity," said David Arida, Senior Vice President of Manufacturing Operations at Dexcom.

Jack Lyons, Vice President Biopharma and Life Sciences Southeast Asia at Exyte shares, "We are delighted to be selected as the main contractor and trusted partner in delivering the first manufacturing facility for Dexcom in Asia and enabling a quick time to market for our client."

About Exyte

Exyte is a global leader in the design, engineering and delivery of facilities for high-tech industries. With a history of more than 100 years, the company has developed a unique expertise in controlled and regulated environments. Exyte has a truly global footprint, serving the most technically demanding clients in markets such as semiconductors, batteries, pharmaceuticals, biotechnology, and data centers. The company offers a full range of services from consulting to the managing of turnkey solutions - delivered to the highest quality and safety standards. Solving the most complex challenges, Exyte forges trusted, long-lasting relationships with its clients. In 2019, Exyte generated sales of EUR 3.9 billion with around 5,200 highly experienced and motivated employees. The company is ideally positioned to further strengthen its market leadership with its broad industry insight and its exceptional talents.

Photo - https://mma.prnewswire.com/media/1487099/Dexcom_Office.jpg
Logo - https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg

Contact

Adriana Williams
Vice President Corporate Communications
and Investor Relations
+49 711 8804 1489
adriana.williams@exyte.net
www.exyte.net

Exyte Logo

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.